Sarepta Therapeutics Appoints Renowned Biotech Executive John C. Martin to its Board of Directors
January 13 2020 - 08:30AM
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision
genetic medicine for rare diseases, announced that it has appointed
John C. Martin, Ph.D., to its Board of Directors, effective today.
Dr. Martin brings decades of executive leadership to Sarepta’s
board, having played an instrumental role in building one of the
world’s foremost biotechnology companies. During his 20-year tenure
as chief executive officer of Gilead Sciences, he oversaw the
growth of the company and development of its scientific portfolio
into 24 marketed products.
“John’s business record is unparalleled, and he
brings expertise and insight gleaned from leading the long-term,
transformational growth of one of the industry’s premier companies
that will add to the strength of the Sarepta board. We are
incredibly fortunate to welcome him to the company’s board of
directors,” said M. Kathleen Behrens, Ph.D., Chairperson of
Sarepta’s Board of Directors.
“Having introduced curative therapies, John’s
vision, acumen, and wisdom are unique in our industry. As Sarepta
prepares to deliver one-time therapies for rare diseases, John’s
strategic guidance as a member of the company’s board will be
invaluable as we work to change the model for how rare diseases are
treated,” said Doug Ingram, Sarepta’s president and chief executive
officer.
Dr. Martin served as the Executive Chairman and
Chairman of Gilead Sciences, Inc., from March 2016 through March
2019, after having served as Chairman and Chief Executive Officer
from June 2008 through March 2016 and President and Chief Executive
Officer from 1996 through May 2008. He joined Gilead in 1990 as
Vice President, Research and Development. Prior to Gilead, Dr.
Martin held several leadership positions at Bristol-Myers Squibb
and Syntex Corporation. Martin currently serves on the Board of
Directors at The Scripps Research Institute and Kronos Bio.
Additionally, he served on the Centers for Disease Control/Health
Resources and Services Administration’s Advisory Committee on HIV
and STD Prevention and Treatment and was a member of the
Presidential Advisory Council on HIV/AIDS. In 2008, Dr. Martin was
inducted into the National Academy of Engineering and, in 2019, he
received the National Academy of Sciences Award for Chemistry in
Service to Society.
Dr. Martin holds a Ph.D. in organic chemistry
from the University of Chicago, an MBA from Golden Gate University
and a B.S. degree in chemical engineering from Purdue
University.
Heidrick & Struggles led the search process
for Sarepta.
About Sarepta
TherapeuticsSarepta is at the forefront of precision
genetic medicine, having built an impressive and competitive
position in Duchenne muscular dystrophy (DMD) and more recently in
gene therapies for Limb-girdle muscular dystrophy diseases (LGMD),
Charcot-Marie-Tooth (CMT), MPS IIIA and other CNS-related
disorders, totaling over 20 therapies in various stages of
development. The Company’s programs and research focus span several
therapeutic modalities, including RNA, gene therapy and gene
editing. Sarepta is fueled by an audacious but important mission:
to profoundly improve and extend the lives of patients with rare
genetic-based diseases. For more information, please visit
www.sarepta.com.
Forward-Looking StatementsThis
press release contains forward-looking statements. Any statements
contained in this press release that are not statements of
historical fact may be deemed to be forward-looking statements.
Words such as "believes," "anticipates," "plans," "expects,"
"will," "intends," "potential," "possible" and similar expressions
are intended to identify forward-looking statements. These
forward-looking statements include statements regarding the
expectation that Dr. Martin’s expertise and insight will add to the
strength of the Sarepta board and that Dr. Martin’s strategic
guidance will be invaluable as Sarepta prepares to deliver one-time
therapies for rare diseases; and Sarepta’s mission to profoundly
improve and extend the lives of patients with rare genetic-based
diseases.
These forward-looking statements involve risks
and uncertainties, many of which are beyond Sarepta’s control.
Known risk factors include, among others: Sarepta may not be able
to execute on its business plans, including meeting its expected or
planned regulatory milestones and timelines, clinical development
plans, and bringing its products to U.S. and ex-U.S. markets for
various reasons including possible limitations of company financial
and other resources, manufacturing limitations that may not be
anticipated or resolved for in a timely manner, and regulatory,
court or agency decisions, such as decisions by the United States
Patent and Trademark Office with respect to patents that cover
Sarepta’s product candidates; and those risks identified under the
heading “Risk Factors” in Sarepta’s most recent Annual Report on
Form 10-K for the year ended December 31, 2018 and most recent
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission (SEC) as well as other SEC filings made by the
Company which you are encouraged to review.
Any of the foregoing risks could materially and
adversely affect the Company’s business, results of operations and
the trading price of Sarepta’s common stock. For a detailed
description of risks and uncertainties Sarepta faces, you are
encouraged to review Sarepta's 2018 Annual Report on Form 10-K and
most recent Quarterly Report on Form 10-Q filed with the Securities
and Exchange Commission (SEC) as well as other SEC filings made by
Sarepta. We caution investors not to place considerable reliance on
the forward-looking statements contained in this press release.
Sarepta does not undertake any obligation to publicly update its
forward-looking statements based on events or circumstances after
the date hereof.
Internet Posting of
InformationWe routinely post information that may be
important to investors in the 'For Investors' section of our
website at www.sarepta.com. We encourage investors and
potential investors to consult our website regularly for important
information about us.
Source: Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. Investors: Ian
Estepan, 617-274-4052iestepan@sarepta.com Media:Tracy Sorrentino,
617-301-8566tsorrentino@sarepta.com
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Mar 2023 to Mar 2024